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What is new in stroke imaging and intervention? 
 
ABSTRACT 
Recent updates to guidelines round brain imaging in stroke and TIA are reviewed.  
A more detailed examination of advanced brain imaging in acute stroke is presented.  
The recent evidence round endovascular mechanical thrombectomy in acute stroke is 
reviewed.  
The implications of delivering thrombectomy are discussed.  
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Recent years have seen significant changes in the imaging and treatment of stroke. As 
thrombolytic therapy revolutionised stroke services over the last 15 years, endovascular 
therapy promises to be just as transformative over the next 5-10. 
 
The use of brain imaging in transient ischaemic attack assessment 
 
The January 2017 NICE guidelines update to TIA assessment reports that patients first require 
assessment by a specialist, with brain imaging only being requested if the specialist deems it 
may alter management.1 This is in accordance with updated 5th Edition of the National Clinical 
Guideline for Stroke (NCGS).2 If acute haemorrhage is the clinical concern then CT brain 
suffices. 
 
The use of brain imaging in acute stroke assessment 
 
For cases of suspected acute stroke, non-contrast computed tomography (NCCT) brain 
examination is the mainstay of imaging as it is a reliable, universally available and cost-
effective means of assessment. NCCT brain imaging can exclude stroke mimics and 
differentiate between an ischaemic and haemorrhagic stroke. For patients eligible for early 
treatment or those with signs of a moderate/severe stroke, NICE and the NCGS have 
recommended that a NCCT brain exam is performed “immediately” or at least within an hour 
of presentation.3  
 
The diagnostic utility of a NCCT brain imaging is well established, but it can also provide an 
indication of prognosis. The Alberta Stroke Programme Early CT Score is a means of deriving 
prognostic information for patients with an anterior circulation stroke.4 The cerebrum is 
divided into 10 topographic regions. For each region affected by an anterior circulation 
infarction, a point is deducted. The stroke affected regions are best assessed with a narrow 
window width and window level, e.g. between 35 and 45 Hounsfield units. Good 
interobserver reproducibility is seen with this scoring method.5 A score of fewer than 8 is an 
indicator of an increased risk of symptomatic intracranial haemorrhage and of a worse 
outcome following intravenous thrombolysis.  
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Advances in the imaging of acute ischaemic stroke 
 
Following the diagnosis of an acute ischaemic stroke, it is established practice to administer 
intravenous thrombolysis (IVT) within 4.5 hours of the onset of symptoms.6 However, IVT is 
not without its risks. In fact, a 6% increase in symptomatic intracerebral haemorrhage was 
noted by a Cochrane systematic review.6  
Is advanced brain imaging able to better select patients for treatment by identifying those 
who are at an increased risk of complications, such as symptomatic intracerebral 
haemorrhage? Could imaging also identify patients who may benefit from treatment despite 
not presenting within 4.5 hours of symptom onset? 
 
Advanced brain imaging in stroke consists of all magnetic resonance imaging (MRI) and any 
form of CT imaging other than a NCCT brain scan.  
 
CT angiography 
 
CT angiography (CTA), from aortic arch to skull vertex, has a variety of clinical benefits as well 
as being quick and cheap to perform. Firstly, it adds diagnostic certainty to the NCCT brain 
scan. CTA can identify the location of the arterial occlusion, which is essential if proceeding 
on to endovascular therapy.7 Furthermore, the degree of any vessel stenosis can be identified, 
which is relevant for both the acute and long term management of patients.8 A recent study 
based on multiple randomised control trials of individual patient record [IPR] data found that 
use of IVT was associated with an improvement in functional outcome if CTA demonstrated 
arterial obstruction [see Figure 1] but not if CTA were normal.9 If this result is corroborated 
by future research, ASPECTS or CTA could be used to spare some patients exposure to the 
risks of thrombolytics, if they are unlikely to benefit from their use. Despite symptoms and 
NCCT brain imaging consistent with an ischaemic stroke, many patients will have patent intra-
cerebral vasculature on CTA, probably around 60%.10,11 
 
The volume of ischaemic tissue can be estimated from CTA. Those patients with a large 
“ischaemic core” receive less benefit from thrombolysis. Indeed, the presence of a large 
ischaemic core is considered to be a relative contraindication to thrombolysis.12 
4 
 
 
CTA is also able to detect the presence and extent of collateral blood supply. A multiphase CT 
angiogram allows even better delineation of collateral supply as it provides progressive, 
temporal information on the blood flow.13 A greater collateral blood supply may justify the 
extension of the reperfusion time window. Conversely, those patients with a lack of collateral 
blood vessels are unlikely to see benefit from endovascular therapy, and could be deemed 
ineligible for this treatment on these grounds.14  
  
CT perfusion  
 
CT perfusion imaging uses sequential brain imaging to evaluate the flow of contrast through 
cerebral vessels (mean transit time), the total cerebral blood volume, and the cerebral blood 
flow to a region. With this information, the extent of reversible and irreversible ischaemic 
tissue can be estimated. Reversibly injured tissue can be estimated using a time to peak of 
greater than six seconds.15 The extent of irreversible damage can be assessed by identifying 
tissue with a 30% lower cerebral blood flow than the normal brain parenchyma.16 If the 
ischaemic core volume is greater than 70-100ml, then there is a low chance of functional 
outcome regardless of the treatment delivered. Care should be taken when interpreting CT 
perfusion scans in patients with confounding pathology, such as arrhythmias, low cardiac 
output or aortic valvular disease. The interpretation of CT perfusion scans can also be 
impaired by technical issues, such as patient movement, timing of the bolus, and the spatial 
separation of slices.  
 
MRI  
 
Patients with signs of a stroke without evidence of ischaemia on CT, can be imaged with 
diffusion weighted MRI sequences as signs of ischaemia appear on MRI earlier than on CT 
imaging. Despite MRI being more sensitive to the early changes in ischaemic stroke, 
systematic review found that approximately one-third of patients with a clinical diagnosis of 
a “minor stroke” were found to have no corroborative signs on MRI.17 For those patients who 
are not able to report the time of symptom onset, diffusion weighted MRI coupled with fluid 
attenuated inversion recovery sequences may be able to time strokes accurately.18 The lack 
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of CT evidence for ischaemia does not negate the requirement for treatment. Therefore, 
although an MRI to confirm ischaemia may be satisfying for clinicians, it is not a requirement 
for the acute management. Furthermore, as MRI takes longer than a CT scan, it is less safe in 
the acutely unwell patient and more susceptible to motion artefacts. 
  
As immediate access to MRI is limited in the UK, it is not a practical alternative to CT imaging 
in most stroke patients but is required in some circumstances.2,7 
 
PET techniques 
 
The role of PET techniques in the acute management of human stroke has been little studied. 
The severe time constraints in clinical practice make it extremely challenging to access PET 
imaging and these are therefore unlikely to enter routine clinical practice in the immediate 
future.  
 
The role of endovascular techniques in the treatment of acute ischaemic stroke 
 
IVT is least effective in large artery occlusive (LAO) stroke where recanalisation rates are 
low.8,10,11 As a result, functional clinical outcomes in LAO stroke with IVT disappointing- with 
an approximate 25% good functional outcome.19 Recent randomised trials have shown that 
there is no benefit with the use of intra-arterial thrombolysis compared to IVT.20,21 
 
A IPR meta-analysis of five very recent trials [Highly Effective Reperfusion evaluated in 
Multiple Endovascular Stroke trials, HERMES], all of which use CTA for patient selection and 
employ modern devices for clot extraction, constitutes the best evidence so far for the use of 
endovascular clot extraction (mechanical thrombectomy; MT) in acute ischaemic stroke – see 
Figure 2.22 The key finding is that MT of proximal anterior circulation LAO strokes is associated 
with a significantly reduced disability after 90 days when compared to standard medical 
treatment. In order to reduce disability by at least one level on the Modified Rankin Scale, the 
number needed to treat with endovascular therapy is only 2.6. Patients with an ASPECTS of 
≥6 were identified as a subgroup likely to experience a statistical benefit from endovascular 
treatment.  
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The significance of this meta-analysis should not be underestimated. Mechanical 
thrombectomy (using either stent retriever and/or aspiration techniques) combined with IVT 
can now be considered best practice for those previously functionally independent patients 
presenting within 6 hours of a large vessel anterior circulation occlusion, provided ASPECTS is 
≥6 and NIHSS score is ≥6.2 Those patients with a contraindication to thrombolysis, but not to 
thrombectomy, will still benefit from endovascular treatment.22 Although MT has been shown 
to significantly improve outcomes up to 7.3 hours from the onset of symptoms, the relative 
benefit from intervention decreases progressively with time.2 The applicability of the 
technique in the NHS has been confirmed in a small UK trial (PISTE trial) – with the 
clinical/technical outcomes and process times for MT all in line with those seen in HERMES 
meta-analysis.24 
 
Patients presenting beyond the 6 hour time window for MT may still benefit from 
endovascular treatment. These patients can be identified with the use of advanced brain 
imaging. Based on recent trials, the MT window for patients with proven advanced brain 
imaging features of good prognosis may be extended as far as 8-12 hours.25,26  
 
The use of MT for posterior circulation LAO strokes is under investigation. Its efficacy and 
potential role in treatment are promising but yet to be confirmed. Questions pertaining to 
the optimum techniques for endovascular therapy also remain unanswered. The benefit of a 
balloon guide, the difference (if any) between primary aspiration and retrievable stents as a 
means of thrombectomy, and the relative advantages/disadvantages of general anaesthesia 
compared to conscious sedation are all topics of debate. Other areas where the MT data is 
equivocal and requires further evaluation include the treatment of patients with a LAO stroke 
accompanied only by minimal symptoms (i.e. NIHSS score < 6), and the treatment of patients 
with small vessel occlusions. The time window for endovascular and intravenous treatment is 
also being examined by, amongst others, the DAWN and ECASS-4 trials, respectively.27 
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Delivery of mechanical thrombectomy 
 
The imaging and intervention requirements to deliver MT will require substantial 
reconfiguration of stroke services. Streamlined pathways allowing patients in smaller 
hospitals to promptly access interventional services at larger centres are a likely solution.28 
Up to 10% of stroke patients are eligible for MT under current evidence and that may be 
extended with additional trial data in the coming years.29 Investment is needed not only for 
the implementation of the established best practice but also for the further investigation of 
uncertain aspects of endovascular therapy, particularly the precise roles and optimum 
techniques for advanced imaging.30 
 
 
 
Conclusions 
 
The evidence base regarding the imaging and endovascular treatment of acute ischaemic 
stroke has undergone a considerable recent revision. Trials have defined CT angiography as a 
key tool in the selection of patients for both IVT and MT. MT has unequivocal and significant 
benefits for an important subgroup of stroke patients. Further research in this rapidly evolving 
field will reveal refinements to the advances presented in this article. However, 
improvements in service delivery are first needed to fully realise the benefits of the work done 
thus far.  
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Figure Legends 
 
Figure 1: a maximum intensity projection in the axial plane from a CTA demonstrating left 
Middle Cerebral Artery occlusion (arrow). 
 
Figure 2: digital subtraction cerebral angiogram before (a) and b (during) mechanical 
thrombectomy for combined left ICA/MCA occlusion. With stent retriever deployed (arrow) 
the MCA is recanalised (b) and flow restored. Once stent retriever is removed along with the 
clot, normal reperfusion is restored (c) – complete recanalisation. The patient has woken up 
on the table and is now moving, hence blurring of image. Figure d demonstrates the extracted 
clot in the stent retriever. 
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